Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions

Autor: Viviana Claudia Canale, Giuseppe Torini, Maja Solman, Cristina Peggion, Martina Venditti, Antonella Lauri, Giada Cattani, Gianfranco Bocchinfuso, Chiara De Faveri, Jelmer Hoeksma, Paolo Calligari, Sara Bobone, Giulia Fasano, Marco Tartaglia, Lorenzo Stella, Alessio Bocedi, Tommaso Gandini, Giovanna Carpentieri, Fernando Formaggio, Simone Martinelli, Jeroen den Hertog, Elisabetta Flex, Andrea Quercioli, Massimo Sanchez, Valentina Tirelli, Valerio Santucci, Barbara Biondi, Luca Pannone

Publikováno v: Journal of Medicinal Chemistry
Journal of medicinal chemistry, 64(21), 15973-15990. American Chemical Society
Journal of medicinal chemistry (2021). doi:10.1021/acs.jmedchem.1c01371
info:cnr-pdr/source/autori:Bobone, Sara; Pannone, Luca; Biondi, Barbara; Solman, Maja; Flex, Elisabetta; Canale, Viviana Claudia; Calligari, Paolo; De Faveri, Chiara; Gandini, Tommaso; Quercioli, Andrea; Torini, Giuseppe; Venditti, Martina; Lauri, Antonella; Fasano, Giulia; Hoeksma, Jelmer; Santucci, Valerio; Cattani, Giada; Bocedi, Alessio; Carpentieri, Giovanna; Tirelli, Valentina; Sanchez, Massimo; Peggion, Cristina; Formaggio, Fernando; Den Hertog, Jeroen; Martinelli, Simone; Bocchinfuso, Gianfranco; Tartaglia, Marco; Stella, Lorenzo/titolo:Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions/doi:10.1021%2Facs.jmedchem.1c01371/rivista:Journal of medicinal chemistry/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume

We developed a new class of inhibitors of protein-protein interactions of the SHP2 phosphatase, which is pivotal in multiple signaling pathways and a central target in the therapy of cancer and rare diseases. Currently available SHP2 inhibitors targe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8496126c4af6cc863ef8628f307fff54
https://pubmed.ncbi.nlm.nih.gov/34714648